𝗚𝗹𝗼𝗯𝗮𝗹 𝐎𝐫𝐠𝐚𝐧 𝐏𝐫𝐞𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 (𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐) The global organ preservation market size reached US$ 187.9 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 313.4 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032. The market is experiencing stable growth driven by increasing prevalence of organ failures due to chronic disorders, such as liver disease, kidney issues, inflammatory bowel disease, and asthma, shortage of donor organs, and the improving healthcare infrastructure. 𝐆𝐫𝐚𝐛 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/gV8wcTJk 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬: ●𝐑𝐢𝐬𝐢𝐧𝐠 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐁𝐮𝐫𝐝𝐞𝐧: Growing numbers of people with organ-damaging chronic illnesses like COPD and liver disease fuel demand for organ preservation technologies as a potential solution to organ failure. ●𝐋𝐢𝐟𝐞𝐬𝐭𝐲𝐥𝐞 & 𝐃𝐢𝐞𝐭 𝐈𝐦𝐩𝐚𝐜𝐭: Changes in lifestyle and dietary habits contribute to a rise in organ failure, potentially increasing the need for organ preservation methods to extend transplant viability. ●𝐅𝐮𝐭𝐮𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: As chronic obstructive pulmonary disease cases are projected to surge globally, the market for organ preservation solutions may see a corresponding rise to address this growing challenge. 𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐎𝐫𝐠𝐚𝐧 𝐏𝐫𝐞𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲: 21st Century Medicine Inc. Biolife Solutions Inc. Bridge to Life Ltd. Bristol Myers Squibb-Myers Dr. Franz Köhler Chemie GmbH Essential Pharmaceuticals, LLC LLC Lifeline Scientific Inc. OrganOx Ltd. Paragonix Technologies, Inc. Inc. TransMedics, Inc. Waters Medical Systems, LLC (an IGL company) Systems LLC XVIVO PERFUSION LUND AB. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/g6ASCEXk #organpreservationmarket #marketresearch #business #marketanalysis #markettrends #researchreport #marketreport #marketforecast #marketgrowth #businessinsights #industryanalysis #marketoutlook #growthprojections #marketstatistics #competitiveanalysis #trendanalysis #marketinsights #imarcgroup
Sujeet Rai’s Post
More Relevant Posts
-
#TrendingWithImpact: On March 3, 2024, researchers from Pusan National University published a new research paper in Aging's Volume 16, Issue 5, entitled, “FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.” “This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process [...]” #PressRelease: https://lnkd.in/e4nr7Gyi #aging #hyperlipidemia #steatosis #diet #agingresearch #openaccess #openscience #peerreviewed #journal #publication #publishing #meded
-
Medical Devices & Software Developer | Quality Management Consultant | Application Specialist | Laboratory Specialist | Microbiologist | DBA | MSc | IVD | CAP | CBAHI | ISO/IEC 17025:2017 | #OpenToWork
Albumin Albumin is a protein produced by the liver and is an important component of the blood. It serves various functions in the body, including maintaining the osmotic pressure of blood, transporting hormones, drugs, and other molecules, and playing a role in maintaining fluid balance. The albumin blood test measures the level of albumin in the blood. Abnormal albumin levels can indicate various underlying health conditions, including liver disease, kidney disease, malnutrition, or inflammation. Low albumin levels, known as hypoalbuminemia, can be seen in conditions such as liver cirrhosis, chronic kidney disease, malnutrition, gastrointestinal disorders, and severe inflammation. It can also be caused by inadequate protein intake, certain medications, and fluid retention. High albumin levels, known as hyperalbuminemia, are less common and can be associated with dehydration, severe burns, or certain types of cancer. Interpretation of albumin test results should be done by a healthcare professional who can consider your medical history, symptoms, and other laboratory tests. They will be able to provide a comprehensive evaluation and determine the underlying cause of any abnormal albumin levels. If you have concerns about your albumin levels or the results of an albumin test, it is best to consult with a healthcare professional for accurate interpretation and further evaluation. They can provide personalized advice and guidance based on your specific situation. #CAP #CBAHI #Healthcare #Laboratory #Medical #medicaldevices #innovation #diagnosis #health #clinicaldiagnostics #medlabmiddleeast #Device #arabhealth #Instrument #Specialist #Technician #Patient #Quality #Safety #Hematology #CBC #Biochemistry #spectrophotometer #Bioassay #Chemiluminescence #immunoassay #type #ELISA #Cobas #Vitros #Abbott #Siemens #IVD #Beckman #Roche #Sysmex #Danaher #Human #Diagnostic #Mindray #Snibe #Maglumi #Agappe #OpenToWork #job #work #HR #jobopportunity #opportunity
-
-
Chief Operating Officer at BiOKuris ( A spin-off company of KitoZyme)// Business Development Director at KitoZyme
Delving into unmet medical needs in IBS and highlighting our patented technology's ability to address multiple pathways in IBS pathophysiology marks a pivotal stride in our innovation journey. Gratitude to all involved in this research and the creation of this insightful article!
🌟 Exciting News Alert! 🌟 📣 We are thrilled to share that BiOkuris' latest paper, titled "Chitin-glucan improves important pathophysiological features of IBS," has been accepted and published in the esteemed "World Journal of Gastroenterology." 🔍 This groundbreaking study unravels the intricate mechanisms by which Chitin-Glucan (CG) addresses the key pathophysiological aspects of Irritable Bowel Syndrome (IBS), including visceral analgesia, intestinal inflammation, gut barrier function, and toxin chelation. 💊 The findings underscore CG's promise as a novel therapeutic strategy for individuals suffering from IBS or IBS-like symptoms, offering hope for improved management and quality of life. 📚 For the full details of our study, click here ➡️ https://lnkd.in/enmP5jwQ 👏We would like to thank the authors (Caroline Valibouze, Caroline Dubuquoy Bisiaux, Philippe Chavatte, Michaël Génin, Veronique MAQUET, Salvatore Modica Amore, Pierre Desreumaux, Christel Rousseaux) for the high quality and quantity of research that went into this paper and the Service public de Wallonie (Caroline Louis) for their support to fostering innovation. 💪 This milestone represents a significant step forward in our mission to revolutionize gastrointestinal health, and endorses our nomination as a finalist for the most innovative ingredients of the year at Vitafoods Europe. We look forward to continuing our journey towards groundbreaking advancements in the field. Any questions? 📧info@biokuris.com #IBS #innovation #chitinglucan #gastroenterology
-
-
🌟 Exciting News Alert! 🌟 📣 We are thrilled to share that BiOkuris' latest paper, titled "Chitin-glucan improves important pathophysiological features of IBS," has been accepted and published in the esteemed "World Journal of Gastroenterology." 🔍 This groundbreaking study unravels the intricate mechanisms by which Chitin-Glucan (CG) addresses the key pathophysiological aspects of Irritable Bowel Syndrome (IBS), including visceral analgesia, intestinal inflammation, gut barrier function, and toxin chelation. 💊 The findings underscore CG's promise as a novel therapeutic strategy for individuals suffering from IBS or IBS-like symptoms, offering hope for improved management and quality of life. 📚 For the full details of our study, click here ➡️ https://lnkd.in/enmP5jwQ 👏We would like to thank the authors (Caroline Valibouze, Caroline Dubuquoy Bisiaux, Philippe Chavatte, Michaël Génin, Veronique MAQUET, Salvatore Modica Amore, Pierre Desreumaux, Christel Rousseaux) for the high quality and quantity of research that went into this paper and the Service public de Wallonie (Caroline Louis) for their support to fostering innovation. 💪 This milestone represents a significant step forward in our mission to revolutionize gastrointestinal health, and endorses our nomination as a finalist for the most innovative ingredients of the year at Vitafoods Europe. We look forward to continuing our journey towards groundbreaking advancements in the field. Any questions? 📧info@biokuris.com #IBS #innovation #chitinglucan #gastroenterology
-
-
Bowel Research UK is committed to funding £250,000 in gut microbiome research, investigating how the microbes within us impact the health of our bowels. Apply now! We are accepting proposals for PhDs or project grants of up to £120,000. Applications will be accepted until 17:00 on the 30th of September 2024. The lead applicant of any proposal must be based at a UK institution. Proposals must focus on the following topics: • Links between the gut microbiome and the immune system and/or nutritional status in the development of bowel disease • The role of the gut microbiome in determining/influencing treatment responses • The gut microbiome as a biomarker of health and as a prognostic, diagnostic or predictive marker of bowel disease • Therapeutically modifying the microbiome to prevent or treat bowel conditions (e.g. FMT, IMT, probiotic, prebiotic or synbiotic therapy. This also includes synthetic biology) • The influence of the microbiome in under-represented clinical conditions of the gut e.g. functional conditions such as diarrhoea, constipation, and diverticular disease • Environmental / microbiome interactions and the causation of bowel disease (e.g. microplastics) To find out more information and apply, please visit https://lnkd.in/d9nTRmk #BowelResearch #Microbiome #GutMicrobiome #Bowels #BowelCancer #BowelDisease #IBD #IBS #Crohns #Stoma #Diverticulitis #LynchSyndrome
-
-
Gut microbiome and diabeties
𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝗰𝗲 𝗮𝗻𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲 𝗶𝗻 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 The paper that I'd like to share today stems from a forum on what we know, how we might target, and what we still need to learn about the role of the microbiome in diabetes. https://lnkd.in/dXJdP2qx. The article nicely summarizes the pathophysiology, potential treatments, the gaps in our knowledge (such as the limited knowledge about interactions in the small intestines) and challenges (such as inter-individual variability). Being a central topic in diabetes as well as host-microbiome interaction, the paper extensively discusses the role of several metabolic pathways, too. Full publication: Mariana Byndloss, Suzanne Devkota, Frank Duca, Jan Hendrik Niess, Max Nieuwdorp, Marju Orho-Melander, Yolanda Sanz, Valentina Tremaroli & Liping Zhao. The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia (2024). https://lnkd.in/dm9KSSGx. Freely available under a Creative Commons license: https://lnkd.in/dyuva2r8 #science #metabolism #microbiotaeducation #pharmacology #precisionmedicine
-
-
What a great article about the importance of the microbiome and its implications in diabetes treatment!
𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝗰𝗲 𝗮𝗻𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲 𝗶𝗻 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 The paper that I'd like to share today stems from a forum on what we know, how we might target, and what we still need to learn about the role of the microbiome in diabetes. https://lnkd.in/dXJdP2qx. The article nicely summarizes the pathophysiology, potential treatments, the gaps in our knowledge (such as the limited knowledge about interactions in the small intestines) and challenges (such as inter-individual variability). Being a central topic in diabetes as well as host-microbiome interaction, the paper extensively discusses the role of several metabolic pathways, too. Full publication: Mariana Byndloss, Suzanne Devkota, Frank Duca, Jan Hendrik Niess, Max Nieuwdorp, Marju Orho-Melander, Yolanda Sanz, Valentina Tremaroli & Liping Zhao. The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia (2024). https://lnkd.in/dm9KSSGx. Freely available under a Creative Commons license: https://lnkd.in/dyuva2r8 #science #metabolism #microbiotaeducation #pharmacology #precisionmedicine
-
-
Published today in Springer Nature Group Metabolism. A ground-breaking collaborative study involving researchers from the Toni Vidal-Puig group at the Institute of Metabolic Science-Metabolic Research Laboratories together with multiple institutions around the world, provides an unprecedented unbiased ranking of murine (mouse) dietary models in terms of their proximity to human metabolic dysfunction-associated steatotic liver disease (#MASLD). One of the lead authors - Dr Ioannis Kamzolas: "The extensive collaboration in this study reflects the global commitment to advancing the understanding and treatment of MASLD and this ranking provides an essential resource for pre-clinical MASLD research, aiding in the selection of appropriate in-vivo models to accelerate the development of therapeutic strategies" Read the paper here 👉 https://lnkd.in/eb7J8Qxz Other lead authors Michele Vacca, Lea Mørch Harder Read more 👉
-
⚠ Kidney International's June issue is out! Read the latest news in research, highlights from current literature, comprehensive reviews, and in-depth case studies. Read the editor's pick for this month: ➡️ Time for Action: Recognizing chronic kidney disease as a major non-communicable disease driver of premature mortality https://ow.ly/QQV850RNyOO ➡️ Kidney Protective Mechanisms of SGLT2 Inhibitors: Evidence for a Hemodynamic Effect https://ow.ly/A3tP50RNyON ➡️ SGLT2 Inhibitors Act as Metabolic Transducers to Restore Healthy Nutrient Deprivation and Surplus Signaling in the Kidney https://ow.ly/RKtO50RNyOK ➡️ SGLT2 inhibitor: Two-way superstar in nephrology? https://ow.ly/pVtJ50RNyOH ➡️ Cutting back on low-value healthcare practices supports sustainable kidney care https://ow.ly/mn2L50RNyOG ➡️ A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy https://ow.ly/f2YV50RNyOM ➡️ NELL-1 associated membranous nephropathy linked with skin fairness cream use: insights from an Indian case series https://ow.ly/SnsM50RNyOL Grow professionally with the ISN. Access high-impact scientific and clinical research through our journals. Join/renew your ISN Membership ➡️ https://ow.ly/EHzl50RNyOP #ThisIsISN - Advancing kidney health worldwide. Together.
-
